ClinicalTrials.gg
CompletedNCT00867009Updated Jun 15, 2015Results posted

A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer

A Phase 2 interventional study of Pemetrexed and Cisplatin in Non-Small-Cell Lung Cancer, sponsored by Eli Lilly and Company. Completed at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-15.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 21 open to participants now, 32 under way, 11 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.

Enrollment
78th of 223
113 · median 64
Started
2009
with 20 others
Phase 2
128 of 227
12 open now
Registered
81st of 227
by date
Lead sponsor
40 of 227
Eli Lilly and Company

Among the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 78th largest by enrollment of the 223 interventional ones that give a count, is one of 21 that started in 2009, is one of 128 in phase 2, and was the 81st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will estimate the response rate in patients with advanced or metastatic non-squamous Non-Small Cell Lung Cancer. Patients who don't progress after 4 to 6 cycles of induction treatment with pemetrexed, cisplatin and cetuximab will receive maintenance treatment with pemetrexed and cetuximab.

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must sign an document for clinical and translational research.
  • Patient must have locally advanced or nonsquamous Non-Small Cell Lung Cancer.
  • Patient must have biological tissue available from your diagnosis tumor for detection of some biomarkers (translational research).
  • Patient cannot be receiving nor have received any prior systemic anticancer therapy, immunotherapy, targeted therapy, or biological therapy for your lung cancer (except chemotherapy given after surgery if it has been completed more than one year before the study entry).
  • Patient is allowed to have had prior radiation therapy as long as it was not more than 25% of the bone marrow and did not include the whole pelvis. Prior radiation therapy should be completed at least 2 weeks prior to first study drug. Thoracic radiation must be completed more than 12 weeks before the study entry. You must be recovered from the toxic effects.
  • Patient must have at least 1 measurable tumor lesion according to the (RECIST) guidelines.
  • Patient must at least be able to be physically mobile, take care of yourself, and must be up and about and able to perform light activities such as light housework or office work.
  • Test results assessing the function of blood forming tissue, kidneys, and liver must be satisfactory.
  • Females must be sterile, or on .
  • Males must be on contraception or sterile (for example post-vasectomy).

Exclusion criteria

Exclusion Criteria:

  • Patient cannot have symptomatic central nervous system .
  • Patient cannot have an active infection or other serious condition that your doctor thinks would make you unable to participate.
  • Patient cannot have a serious cardiac condition, such as a heart attack, angina, or heart disease within 6 months of entering the trial.
  • Patient cannot have had a another form of cancer other than superficial basal cell and superficial squamous (skin) cell cancer, or carcinoma in situ of the cervix within the last 5 years.
  • Patient cannot have had significant neurologic or psychiatric disorders including dementia, seizures and bipolar disorder.
  • Patient cannot have moderate or severe peripheral neuropathy
  • Patient cannot have received treatment within 30 days with any experimental drug.
  • Patient cannot have had a major surgery within the last 4 weeks.
  • Patient cannot have previously received treatment with transduction inhibitors or Epidermal Growth Factor Receptor (EGFR)-targeting therapy.
  • Patient cannot have prior known allergic/ reaction to any of the components of study treatments.
  • Females cannot be pregnant or breastfeeding.
  • Patient is unable to stop taking more than 1.3 grams of aspirin on a daily basis or other aspirin like medication (non-steroidal antiinflammatory drugs: NSAIDs) for a few days during each cycle of therapy.
  • Patient is unable or unwilling to take folic acid, injections of vitamin B12, or .
  • Patient cannot have fluid around your lungs or in your abdomen (pleural effusions or ascites) that cannot be controlled by drainage or other procedures.
  • Patient cannot have received a yellow fever vaccination within the previous 30 days or plan to have it.
  • Patient cannot have known drug abuse.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Induction/maintenance Therapy

    pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab

    Drug: Pemetrexed · Drug: Cisplatin · Drug: Cetuximab

Interventions

  • Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation

    Also known as: Alimta, LY231514

  • Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles

  • Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)

    Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions. Tumor response is presented as a percentage (%) and is the number of participants with a CR plus PR divided by the number of participants in the protocol qualified (PQ) population, then multiplied by 100.

    Time frame: From start of treatment until documented best response. (up to 18.9 months)

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is measured from study entry until disease progression, death or date of last contact. Progressive disease (PD) was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. For participants not known to have died or have had objective PD as of the data cutoff date, PFS was censored at the date of the last objective progression-free disease assessment.

    Time frame: From start of treatment until documented disease progression or death from any cause (up to 18.9 months)

  2. The Percentage of Participants Still Living at One Year (One Year Survival Rate)

    The one year survival rate is presented as percentage (%) of participants still living at one year and is the number of participants that are still alive at one year divided by the number of participants in the protocol qualified (PQ) population, which is then multiplied by 100.

    Time frame: One year

  3. The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])

    The DCR is presented as percentage (%) and is the number of participants with a best tumor response of CR, PR, or SD divided by the number of participants in the protocol qualified (PQ) population, then multiplied by 100. Best tumor response of CR, PR, or SD was determined from the sequence of tumor response assessments. Tumor response was assessed using RECIST criteria. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; SD=small changes that do not meet above criteria.

    Time frame: From start of treatment until documented best tumor response (up to 18.9 months)

07

Results

Posted May 16, 2012

Participant flow

Induction Period
Participant flow — Induction Period
MilestonePem/Cis + Cet
Started113
Received at least 1 dose of study drug113
Protocol qualified (pq) population109
Completed51
Not completed62
Withdrew: Nonserious adverse event5
Withdrew: Serious adverse event10
Withdrew: Death due to serious adverse event6
Withdrew: Death due to study disease4
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject8
Withdrew: Physician decision3
Withdrew: Progressive disease (pd)25
Maintenance Period
Participant flow — Maintenance Period
MilestonePem/Cis + Cet
Started51
Completed47
Not completed4
Withdrew: On-going in the study at data cut-off4

Outcome measures

PrimaryPercentage of Participants With a Tumor Response (Objective Tumor Response Rate)

Response was assessed using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions. Tumor response is presented as a percentage (%) and is the number of participants with a CR plus PR divided by the number of participants in the protocol qualified (PQ) population, then multiplied by 100.

Time frame:
From start of treatment until documented best response. (up to 18.9 months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)
percentage of participantsPem/Cis + Cet
Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)38.5
Statistical analysis
  • Pem/Cis + Cet · Percentage of participants with response: 38.5 · 80% CI 32.30 to 45.09
SecondaryProgression-free Survival (PFS)

PFS is measured from study entry until disease progression, death or date of last contact. Progressive disease (PD) was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD = 20% increase in sum of longest diameter of target lesions or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. For participants not known to have died or have had objective PD as of the data cutoff date, PFS was censored at the date of the last objective progression-free disease assessment.

Time frame:
From start of treatment until documented disease progression or death from any cause (up to 18.9 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPem/Cis + Cet
Progression-free Survival (PFS)5.82 (0.03 to 18.89)
Statistical analysis
  • Pem/Cis + Cet · Median number of months: 5.82 · 80% CI 4.40 to 6.70
SecondaryThe Percentage of Participants Still Living at One Year (One Year Survival Rate)

The one year survival rate is presented as percentage (%) of participants still living at one year and is the number of participants that are still alive at one year divided by the number of participants in the protocol qualified (PQ) population, which is then multiplied by 100.

Time frame:
One year
Reported as:
Number · percentage of participants
The Percentage of Participants Still Living at One Year (One Year Survival Rate)
percentage of participantsPem/Cis + Cet
The Percentage of Participants Still Living at One Year (One Year Survival Rate)45
Statistical analysis
  • Pem/Cis + Cet · Percentage of participants with response: 45 · 80% CI 39 to 51
SecondaryThe Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])

The DCR is presented as percentage (%) and is the number of participants with a best tumor response of CR, PR, or SD divided by the number of participants in the protocol qualified (PQ) population, then multiplied by 100. Best tumor response of CR, PR, or SD was determined from the sequence of tumor response assessments. Tumor response was assessed using RECIST criteria. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; SD=small changes that do not meet above criteria.

Time frame:
From start of treatment until documented best tumor response (up to 18.9 months)
Reported as:
Number · percentage of participants
The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])
percentage of participantsPem/Cis + Cet
The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])59.6
Statistical analysis
  • Pem/Cis + Cet · Percentage of participants with response: 59.6 · 80% CI 53.06 to 65.94

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pem/Cis + Cet—61/113 (54%)101/113 (89.4%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventPem/Cis + Cet
AnaemiaBlood and lymphatic system disorders6/113
NeutropeniaBlood and lymphatic system disorders6/113
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/113
ThrombocytopeniaBlood and lymphatic system disorders5/113
VomitingGastrointestinal disorders5/113
LeukopeniaBlood and lymphatic system disorders3/113
DiarrhoeaGastrointestinal disorders3/113
General physical health deteriorationGeneral disorders3/113
DyspnoeaRespiratory, thoracic and mediastinal disorders3/113
Pleural effusionRespiratory, thoracic and mediastinal disorders3/113
Most frequent other events
Showing 10 of 251
Most frequent other events
EventPem/Cis + Cet
RashSkin and subcutaneous tissue disorders62/113
NauseaGastrointestinal disorders51/113
FatigueGeneral disorders37/113
VomitingGastrointestinal disorders34/113
ConstipationGastrointestinal disorders29/113
NeutropeniaBlood and lymphatic system disorders25/113
LeukopeniaBlood and lymphatic system disorders24/113
DiarrhoeaGastrointestinal disorders24/113
StomatitisGastrointestinal disorders23/113
Mucosal inflammationGeneral disorders21/113

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pem/Cis + Cet
Mean59.15 ± 8.83
Sex: Female, Male
Sex: Female, Male(Participants)Pem/Cis + Cet
Female41
Male72
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pem/Cis + Cet
White113
Region of Enrollment
Region of Enrollment(participants)Pem/Cis + Cet
Greece12
Spain25
Austria6
Germany28
Netherlands16
Italy26
Eastern Co-operative Oncology Group (ECOG) Performance Status
Eastern Co-operative Oncology Group (ECOG) Performance Status(participants)Pem/Cis + Cet
0 - Fully Active56
1 - Ambulatory, Restricted Strenuous Activity57
Disease Stage
Disease Stage(participants)Pem/Cis + Cet
Stage IIIB9
Stage IV104
Pathological Diagnosis
Pathological Diagnosis(participants)Pem/Cis + Cet
Adenocarcinoma (Adeno), Breast1
Carcinoma, Adenosquamous,Lung, Predominantly Adeno1
Large Cells Lung Carcinoma5
Malignant Neoplasm, Adeno Lung88
Non-Small Cell Lung (NSCL) Cancer9
Poorly Differentiated Non-Small Cell8
Missing1
08

Study locations

24 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Graz, 8036, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salzburg, 5020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wels, 4600, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 13125, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halle, D-06120, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Homburg, 66421, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mannheim, 68167, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tuebingen, 72076, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 11527, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bari, 70126, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Palermo, 90146, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Potenza, 85028, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Torino, 10100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Treviso, 31100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amsterdam, 1081 HV, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Groningen, 9713 GZ, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Maastricht, 6229 HX, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    S-Hertogenbosch, 5211 NL, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08003, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lleida, 25198, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reus, 43201, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of May 2011 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 23, 2009
Start
Apr 2009
Primary completionActual
May 2011
CompletionActual
Sep 2014
Results first posted
May 16, 2012
Last update
Jun 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00867009
Responsible party
Sponsor
First posted
Mar 23, 2009
Start date
Apr 2009
Primary completion
May 2011
Completion
Sep 2014
Results posted
May 16, 2012
Last update
Jun 15, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Cisplatin · Cetuximab

Start the discussion